Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations

Roy J. Kim, Clara Malattia, Michaela Allen, Thomas Moshang, Mohamad Maghnie

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

Original languageEnglish (US)
Pages (from-to)115-123
Number of pages9
JournalPediatric Endocrinology Reviews
Volume2
Issue numberSUPPL. 1
StatePublished - Nov 1 2004

Keywords

  • Adverse effects
  • Children
  • Desmopressin
  • Diabetes insipidus
  • Vasopressin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations'. Together they form a unique fingerprint.

Cite this